Press

Nexeon Medsytems is a medical device company focused on providing innovative neurostimulation products for patients suffering from debilitating neurological diseases, including Parkinson’s and essential tremor. It was founded in 2005 with the goal of changing how innovative ideas in the medical device industry move from concept to reality, with a focus on creating solutions for clinicians in their pursuit of improving patient outcomes.

NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Nexeon MedSystems, Inc. (OTCQB: NXNN).

Nexeon MedSystems (OTCQB: NXNN) announced today a conference call to discuss 2017 results.  The call is scheduled for 4:00 p.m.  Central Standard Time on November 20th, 2017.   Analysts, investors, and other interested parties may access via conference line (https://www.uberconference.com/nexeon) or dialing an optional dial in number: 469-551-9824.  The call will also be archived on the Company investor relations page.

Feasibility Study for Treatment of Atrial Fibrillation is First Phase of €3.4M BioWin Award

Normally an acquisition and commencing a clinical trial are productive events for a small company, especially those in the hot "medtech" sector, but that hasn't been the case for Nexeon MedSystems Inc. (OTCQB:NXNN). The Belgium-based bioelectronics medical device company with an emphasis on neurological diseases has seen shares slide since they began trading less than a month ago from $2.00 each to under $1.00.

Nexeon MedSystems Inc (OTC:QB “NXNN”) announced today that it has received a Phase I Small Business Research Innovation (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to develop a neurostimulation therapy for asthma in collaboration with researchers at Oregon Health Sciences University. The funding award was granted due to the merits of the proposed development plan for a novel asthma treatment related to airway constriction. This therapy would be a second-line defense for patients whose current medications do not adequately treat their asthma.

Dallas, TX -- Nexeon MedSystems, Inc. (OTC:QB NXNN) announced today that it has commenced "regular way" trading on the OTC Market (OTC:QB) under the symbol "NXNN".  The Company is finalizing development of its deep brain stimulation system for the treatment of symptoms associated with Parkinson's disease. 

Nexeon MedSystems ("Nexeon" or "the Company") (OTCQB: NXNN) announced today that it has exercised its option to acquire Nexeon Medsystems Belgium, SPRL ("NMB").  This Belgian-based company has been operating since 2013 developing neurostimulation products. NMB recently acquired Medi-Line, a Belgian medical device manufacturer with financing support provided by KBC and CBC Bank.  Medi-Line has expertise in active and non-active implants, and it has been profitable for its complete 25-year corporate history. For more information about the transaction, please review the Form 8-K.

SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has initiated coverage on Nexeon MedSystems, Inc. (NXNN) with a 12-month price target of US $2.40.